P2Y purinoceptor 13 (P2RY13)

P2Y purinoceptor 13 (P2RY13) is a G protein-coupled receptor (GPCR) primarily activated by adenosine diphosphate (ADP) and coupled to the Gi signaling pathway [1, 7, 8]. It is widely expressed in the liver, brain, bone marrow, and immune cells, where it plays a critical role in regulating diverse physiological processes such as lipid metabolism, bone homeostasis, and neuroprotection [2, 4, 11]. In the liver, P2RY13 activation promotes reverse cholesterol transport by enhancing the uptake of high-density lipoprotein (HDL)-derived cholesterol, making it a potential target for treating atherosclerosis and hypercholesterolemia [4, 6]. In the skeletal system, it modulates the balance between osteoblast and adipocyte differentiation, and its inhibition has been suggested as a strategy to enhance bone formation in osteoporosis [6, 15]. Furthermore, P2RY13 signaling is involved in protecting neurons from oxidative stress and excitotoxicity, suggesting therapeutic potential in neurodegenerative diseases [4, 13]. While several P2Y12 antagonists like cangrelor show cross-reactivity with P2RY13, the development of selective modulators remains an active area of research to minimize off-target effects and harness its tissue-specific benefits [11, 12].

Other names

P2Y13Purinergic receptor P2Y13G-protein coupled receptor 86 (GPR86)G-protein coupled receptor 94 (GPR94)FKSG77GPCR1SP174

Agonism or antagonism of the Gi-coupled purinergic signaling pathway, which inhibits adenylate cyclase and reduces intracellular cAMP levels to modulate metabolic and protective cellular responses [4, 11, 12].